Nobiletin-rich Citrus reticulata peels, a kampo medicine for Alzheimer's disease: A case series

Geriatrics and Gerontology International

Volumn 13, Issue 1, 2013, Pages 236-238

  Seki, Takashi ^a   Kamiya, Tetsuharu ^a   Furukawa, Katsutoshi ^b   Azumi, Masako ^c   Ishizuka, Satoshi ^c   Takayama, Shin ^a   Nagase, Satoru ^a   Arai, Hiroyuki ^b   Yamakuni, Tohru ^b   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Sendai Tomizawa Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; KAMPO; NOBILETIN;

AGED; ALZHEIMER DISEASE; CITRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG RESPONSE; FAMILY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LETTER; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; ANTIOXIDANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS; DISEASE PROGRESSION; FLAVONES; HUMANS; INDANS; JAPAN; MEDICINE, KAMPO; PHYTOTHERAPY; PIPERIDINES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84872002328     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2012.00892.x     Document Type: Letter

References (10)

1. Matsuzaki K, Yamakuni T, Hashimoto M etal. Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neurosci Lett 2006; 400 (3): 230-234.
2. Nakajima A, Yamakuni T, Matsuzaki K etal. Nobiletin, a citrus flavonoid, reverses learning impairment associated with N-methyl-D-aspartate receptor antagonism by activation of extracellular signal-regulated kinase signaling. J Pharmacol Exp Ther 2007; 321 (2): 784-790.
3. Onozuka H, Nakajima A, Matsuzaki K etal. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 326 (3): 739-744.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (7): 939-944.
5. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327 (7407): 128-132.
6. in t' Veld BA, Ruitenberg A, Hofman A etal. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345 (21): 1515-1521.
7. Caballero J, Nahata M. Do statins slow down Alzheimer's disease? A review. J Clin Pharm Ther 2004; 29 (3): 209-213.
8. Ohrui T, Matsui T, Yamaya M etal. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52 (4): 649-650.
9. Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (3): 189-198.
10. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19 (3): 448-450.